Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses (2013 - 2018)

Alnylam Pharmaceuticals (ALNY) has reported Other Accumulated Expenses for 6 consecutive years, with $23.6 million the latest figure, recorded in Q4 2018.

• For the quarter ending Q4 2018, Other Accumulated Expenses rose 117.66% year-over-year to $23.6 million; the trailing twelve-month figure through Dec 2018 stood at $23.6 million (up 117.66% YoY), and the FY2018 full-year result was $23.6 million, up 117.66% from the prior year.
• Other Accumulated Expenses climbed to $23.6 million in Q4 2018 per ALNY's latest filing, from $10.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $25.4 million in Q1 2014 and bottomed at $3.8 million in Q4 2014.
• Historically, Other Accumulated Expenses has averaged $13.5 million across 5 years, with a median of $11.7 million in 2016.
• The sharpest annual moves came in 2016 and 2017: Other Accumulated Expenses surged 154.34% in 2016, then retreated 14.02% in 2017.
• Over 5 years, Other Accumulated Expenses stood at $3.8 million in 2014, then soared by 30.38% to $5.0 million in 2015, then jumped by 154.34% to $12.6 million in 2016, then declined by 14.02% to $10.9 million in 2017, then soared by 117.66% to $23.6 million in 2018.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $23.6 million, $10.9 million, and $12.6 million for Q4 2018, Q4 2017, and Q4 2016 respectively.